Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q4 FY26 Earnings Presentation
20 slides from Fermenta Biotech's earnings presentation, May 28, 2026
Slide 1: Intimation of Earnings Presentation to BSE
May 28, 2026 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation – Q4/FY26 Ref: Scrip Code: 506414 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulatio
Slide 2: Fermenta Biotech Ltd Q4/FY26 presentation
Fermenta Biotech Ltd Q4/FY26 presentation 26 May 2026
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Fermenta provides best-in-class, scientifically-validated nutritional ingredients
Fermenta provides best-in-class, scientifically-validated nutritional ingredients for the world’s leading brands in the pharmaceutical, dietary supplement, food and beverage, and veterinary and animal feed industries. Our edge? Decades of expertise in global-scale, high-value manufacturing, and rese
Slide 5: Q4/FY26 Highlights
Q4/FY26 Highlights Financials (consolidated) with Real Estate Performance Q4FY26 FY26 FY26 revenue (ex-real estate) up 27% YoY at INR 546 crore INR 126.6 crore INR 547.8 crore Revenue Vitamin D3 Human Nutrition +28% YoY at (down 12% YoY, down 10% QoQ) (up 14% YoY) INR 293 crore Vitamin D3 Anim
Slide 6: Consolidated Key Financials
Consolidated Key Financials The recovery continues, with financials strong all-round 117 (₹ Crore) 548 (₹ Crore) 407 481 43 41 Revenue Cash flow from operations 105 93 359 347 122 122 205 193 236 70 Net Fixed Assets 210 206 EBITDA 39 217 26 70 236 132 76 Total Debt 109 109 15 PAT 92 (24) 58 (53) Cas
Slide 7: Lines of Business
Lines of Business Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 - Human Vitamin D3 - Animal Others Premium supplements, food Specialized formulations for Vitamin D analogs and specialized fortification, and pharmaceuticals livestock
Slide 8: Nutrition: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) (₹ Crore) % change 1% FY24 FY25 FY26 FY25 Vs FY26 7% 8% Nutrition Business 217 350 436 18% 3% 15% Vitamin D3 - Human Nutrition 141 228 293 +28% 14% 6% Vitamin D3 - Animal Nutrition 38 82 109 +32% Others 9% 6% Others 39 40 34 -16% 13% D3 – Animal Other Business 46 67 83 11%
Slide 9: Performance Ratios (Consolidated)
Performance Ratios (Consolidated) Higher Profitability | Stronger Balance Sheet FY 23 FY 24 FY 25 FY 26 Liquidity Liquidity strengthens, leverage falls, Current 1.2 1.4 1.58 1.86 interest cover expands. Profitability Quick 0.5 0.8 0.87 0.99 moderates from FY25 peak but stays Asset management well ab
Slide 10: Key Balance Sheet Items
Key Balance Sheet Items Growth with Financial Agility (₹ Crore) FY25 FY26 Comments Assets Cash up 30% YoY; gross debt held Total Assets 614 648 Asset base broadly steady; mix shifts to liquidity flat. Net debt halved on a stronger asset base Fixed Assets (Net) 210 206 Depreciation outpaces capex; gr
Slide 11: Cash Flow
Cash Flow (₹ Crore) FY25 FY26 Comments Operating Cash Flow Net Profit 83 96 Net profit base scales up; sustained delivery Depreciation 24 22 Charge broadly flat; gross block stable Free cash flow more than triples to Working Capital Changes (78) (16) WC absorption sharply lower YoY INR 62 crore as o
Slide 12: Cost Breakdown (% of Revenue)—w/o Real Estate
Cost Breakdown (% of Revenue)—w/o Real Estate Optimization Drives Margin Expansion & Operational Efficiency Cost Components FY25 FY26 Change Key Drivers Raw Materials 38% 37% Improved sourcing mix Employee Cost 15% 16% Capacity expansion adds heads Manufacturing Expenses 15% 12% Operating leverage o
Slide 13: Customer Concentration (Without Real Estate)
Customer Concentration (Without Real Estate) Well-Diversified Base with Balanced Revenue Distribution Low single-customer dependency with the largest Concentration risk well-managed; long tail of accounts customer contributing just 9% of total revenue. Only 2 broadens the revenue base customers indi
Slide 14: The Opportunity
The Opportunity Leverage Fermenta’s strengths towards meeting evolving consumer needs and regulatory requirements across diverse markets India Global Innovation Drivers Preventive health awareness Nutritional supplements Nutrigenomics Growing middle class Aging drives vitamin D Natural/o
Slide 15: Fermenta's Value Proposition
Fermenta’s Value Proposition Society Contribute to global health and preventive care through nutritional ingredients Support life productivity across human and animal populations Address environmental challenges with custom and green chemistry solutions Best-in-class, science-backed Market leadershi
Slide 16: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Dedicated Vitamin D3 with Kullu Certifications: WHO-GMP, USFDA, backward integration for Himachal Pradesh FSSC, HALAL, KOSHER, GAIN etc. cholesterol Collaboration with toll Multiple global regulatory Dahej manufactur
Slide 17: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier food te
Slide 18: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions API New products Commercialized 11 products including Vitamin Calcefediol commercialization K1, Cholesterol, Lanolin derivatives Process improvement Vitamin D3 analogs development Cost optimization for Vitamin K1 process Yield e
Slide 19: Example R&D Outcomes
Example R&D Outcomes Strategic Product Portfolio Will Drive Future Revenue Growth Spray-Dried Vitamin D3 VITADEE Green P Customized Premixes ✔ Plant-based Vitamin D3 with clean-label ✔ Equipped with advanced instrumentation and ✔ Patented 100,000 IU/g for vegan supplement markets pilot-scale equipme
Slide 20: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd